Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ES2B-C001 + Montanide ISA 51 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ES2B-C001 | ES2BC001|ES2B-= C001 | ES2B-C001 is a vaccine comprising virus-like particles targeting ERBB2 (HER2), which potentially increase antitumor immune activity against ERBB2 (HER2)-expressing tumors (PMID: 36289916) | ||
| Montanide ISA 51 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06746688 | Phase I | ES2B-C001 + Montanide ISA 51 | The Trial is a First-in-human, Phase I, Open-label, Dose-escalating Trial to Assess the Safety and Tolerability of ES2B-C001 Combined With Montanide or Without Montanide, in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Expressing Metastatic Breast Cancer | Recruiting | AUT | 0 |